| Bruton's Tyrosine Kinase as Anti-Cancer Drug Target DS Conklin, C Eifert, A Kourtipis, L Kokabee, W Xiauhui US Patent App. 17/497,571, 2022 | | 2022 |
| Palmitoylation of the alternative amino terminus of the BTK-C isoform controls subcellular distribution and signaling M Kokabee, X Wang, E Voorand, E Alin, L Kokabee, F Khan, S Desrosiers, ... Cancer Genomics & Proteomics 19 (4), 415-427, 2022 | 3 | 2022 |
| Evaluating in vivo efficacy of anti-VSIG4 antibodies in humanized B-hVSIG4 mice R Lyu, C Shang, L Kokabee, Y Nie, Y Yang Cancer Research 82 (12_Supplement), 1642-1642, 2022 | | 2022 |
| Evaluating in vivo efficacy of bi-functional fusion protein anti-PD-1-IL21 in humanized B-hIL21R mice and B-hPD-1/hIL21R mice R Lyu, Z Li, L Kokabee, J Yao, Y Nie, C Guo Cancer Research 82 (12_Supplement), 1641-1641, 2022 | | 2022 |
| Bruton's tyrosine kinase as anti-cancer drug target DS Conklin, C Eifert, A Kourtidis, X Wang, L Kokabee US Patent 11,149,092, 2021 | | 2021 |
| Bruton’s tyrosine kinase and its isoforms in cancer X Wang, L Kokabee, M Kokabee, DS Conklin Frontiers in cell and developmental biology 9, 668996, 2021 | 25 | 2021 |
| Humanized IL6/hIL6R mouse model supports the evaluation of therapeutic drug candidates targeting to human IL6 and IL6 receptor L Zhao, Y Mao, L Wang, Y Chen, L Kokabee, Q Lin Cancer Research 81 (13_Supplement), 2953-2953, 2021 | | 2021 |
| Humanized CCR8 mouse model provides a translational tool for anti-human CCR8 antibody drug development L Wang, C Shang, J Zhang, Y Chen, L Kokabee, Q Lin Cancer Research 81 (13_Supplement), 2954-2954, 2021 | | 2021 |
| Humanized IL17A/hIL17F mouse model provides a preclinical tool for the evaluation of therapeutic drugs targeting to IL-17 pathway C Li, L Zhao, T Zhu, Y Chen, L Kokabee, C Guo Cancer Research 81 (13_Supplement), 2956-2956, 2021 | | 2021 |
| Bruton's tyrosine kinase as anti-cancer drug target DS Conklin, X Wang, L Kokabee US Patent 10,421,820, 2019 | | 2019 |
| Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells S Beaudin, L Kokabee, JE Welsh Oncotarget 10 (23), 2292, 2019 | 14 | 2019 |
| NDRG1 regulates neutral lipid metabolism in breast cancer cells CJ Sevinsky, F Khan, L Kokabee, A Darehshouri, KR Maddipati, ... Breast Cancer Research 20, 1-17, 2018 | 80 | 2018 |
| The effect of vitamin K on aggressiveness, lipid metabolism and gene expression in triple-negative breast cancer cells L Kokabee, S Beaudin, JE Welsh Cancer Research 78 (13_Supplement), 5170-5170, 2018 | | 2018 |
| Vitamin K pathway functions in triple-negative breast cancer S Beaudin, L Kokabee, JE Welsh Cancer Research 78 (13_Supplement), 790-790, 2018 | | 2018 |
| Bruton's tyrosine kinase as anti-cancer drug target DS Conklin, C Eifert, A Kourtidis, X Wang, L Kokabee US Patent 9,637,554, 2017 | 1 | 2017 |
| Bruton's tyrosine kinase inhibitors prevent therapeutic escape in breast cancer cells X Wang, J Wong, CJ Sevinsky, L Kokabee, F Khan, Y Sun, DS Conklin Molecular cancer therapeutics 15 (9), 2198-2208, 2016 | 55 | 2016 |
| Bruton's Tyrosine Kinase as Anti-Cancer Drug Target DS Conklin, C Eifert, A Kourtidis, X Wang, L Kokabee US Patent App. 14/913,241, 2016 | | 2016 |
| Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer L Kokabee, X Wang, CJ Sevinsky, WLW Wang, L Cheu, SV Chittur, ... Cancer biology & therapy 16 (11), 1604-1615, 2015 | 51 | 2015 |
| The expression pattern of APC2 and APC7 in various cancer cell lines and AML patients H Rahimi, A Ahmadzadeh, S Yousef-amoli, L Kokabee, MA Shokrgozar, ... Advances in Medical Sciences 60 (2), 259-263, 2015 | 17 | 2015 |
| Bruton's tyrosine kinase as anti-cancer drug target DS Conklin, C Eifert, A Kourtidis, X Wang, L Kokabee US Patent 9,095,592, 2015 | 22 | 2015 |